Overall, CpG-ODNs and BUD synergistically improved adverse CS-exposure asthma outcomes and inhibited, at least in part, RORt-mediated Th17 response by restoring HDAC2 expression and activity, consequently ameliorating GCs insensitivity. This evidence concerns the gene HDAC2 and asthma.